A revolutionary breakthrough in accessibility technology has been demonstrated as Apple's brain-computer interface (BCI) protocol successfully enabled a patient with ALS to control an iPad using nothing but their thoughts. This marks the first public demonstration of Apple's neural interface technology in action, representing a significant leap forward in assistive technology for individuals with severe mobility limitations.
 |
|---|
| A person with ALS engaged with a tablet, showcasing the revolutionary BCI technology that allows control through thought |
The Technology Behind the Breakthrough
The demonstration showcases Apple's BCI capabilities integrated into iOS 26 and iPadOS 26, working in conjunction with Synchron's Stentrode implantable device. Mark Jackson, who lives with amyotrophic lateral sclerosis (ALS), served as the test participant in this groundbreaking display. The Stentrode device, which has received FDA approval for trials, reads brain signals through electrodes and translates them into digital commands that the iPad can understand.
Minimally Invasive Implementation
Unlike more invasive brain-computer interfaces that require direct electrode implantation into brain tissue, Synchron's approach offers a safer alternative. The Stentrode device is inserted through the jugular vein using a minimally invasive endovascular procedure, similar to stent placement procedures. The device is positioned on the surface of blood vessels in the brain's motor cortex, eliminating the need for open-brain surgery and significantly reducing associated risks.
Real-World Demonstration Capabilities
In the demonstration video, Jackson successfully navigated the iPad's home screen, opened applications, and composed messages entirely through thought-based commands. The system utilizes Apple's new BCI Human Interface Device (HID) protocol, which enables native thought-driven control of Apple devices. While the response time may not match traditional touch or voice inputs, the technology represents a transformative solution for individuals with conditions that severely limit physical movement.
Expanding Patient Access
Synchron has successfully implanted the Stentrode device in ten patients across the United States and Australia as of May 2024. Jackson became one of the first recipients in 2023, participating in Synchron's COMMAND research study. The company's approach contrasts with other neural interface technologies, such as Neuralink's N1 chip, which requires more invasive direct brain tissue implantation.
Future Development and Applications
Apple plans to release developer tools later this year, enabling the creation of thought-controlled applications for various use cases. The BCI capabilities are being integrated as part of Apple's accessibility features, extending potential support to iPhone, Mac, and Apple Vision Pro devices. Dr. Tom Oxley, co-founder of Synchron, describes this milestone as providing a glimpse into the future of human-computer interaction, where cognitive input could become a mainstream control method.
This breakthrough represents more than a technical achievement; it opens new possibilities for individuals with spinal cord injuries, ALS, and other conditions that limit traditional device interaction methods. As the technology continues to develop, it may fundamentally change how people with mobility challenges access and interact with digital devices.
